Veradermics reports positive 12-month Phase 3 data in male pattern hair loss
MANE•Veradermics said VDPHL01 increased hair count by 43.9 hairs/cm² with twice-daily dosing and 29.7 hairs/cm² with once-daily dosing at month 12, with no new safety signals. The company plans to announce female pattern hair loss study 306 data in the first half of 2027.
1. Phase 3 results
Veradermics reported positive 12-month data from study 302 in male pattern hair loss. VDPHL01 increased hair count by 43.9 hairs/cm² with twice-daily dosing and 29.7 hairs/cm² with once-daily dosing, and showed a favorable safety profile with no new safety signals. The company said it plans to announce study 306 data in female pattern hair loss in the first half of 2027.
